The approval of Pola-R-CHP for DLBCL and subpopulations that benefit the most
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2025-02-13
Просмотров: 443
Описание:
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the recent FDA approval of a combination of polatuzumab vedotin plus R-CHP (Pola-R-CHP) for patients with previously untreated diffuse large B-cell lymphoma (DLBCL), based on findings from the POLARIX trial (NCT03274492). Dr Strati notes subpopulations that may benefit the most from this combination, including those with non-GCB phenotypes and high-risk patients with a high International Prognostic Index (IPI). This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
